Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study

Zhihao Lü; Li Kong; Buhai Wang; Junye Wang; Lianke Liu; Yongqian Shu; Lei Yang; Guogui Sun; Guochun Cao; Yinghua Ji; Tongjian Cui; Hu Liu; Wensheng Qiu; Na Li; Gaofeng Li; Hui Luo; Xinfang Hou; Yanqiao Zhang; Wenbin Yue; Liying Xue; Zheng Liu; Yueyin Pan; Shegan Gao; Xiuwen Wang; Zhanyu Pan; Shuqun Zhang; Gen Lin; Yanru Xie; Kangsheng Gu; Tiejun Ren; Weidong Li; Tao Li; Shoufeng Wang; Wei He; Yun Fan; Jun Liang; Bing Xia; Li Zhao; Shuxuan Wang; Lin Shen

doi:10.1016/j.eclinm.2024.102623

Abstract

In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here, we report effect of sintilimab plus chemotherapy on health-related quality of life (HRQoL) in patients with advanced ESCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lü et al. (2024) studied this question.

synapsesocial.com/papers/68e69859b6db64358761ec64 https://doi.org/10.1016/j.eclinm.2024.102623

View Full Paper

Ask AI

Bookmark

Share

Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study

Abstract

Discussion

Cite This Study

Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading